NCT05864105 - PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL

PM8002

PM8002 20mg/kg Q2W

DRUG

FOLFOX regimen

day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]

Trial Locations (9)

Unknown

Anhui Provincial Hospital, Hefei

Fujian Cancer Hospital, Fuzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

Henan Cancer Hospital, Zhengzhou

The Third Xiangya Hospital of Central South University, Changsha

The First Hospital of Jilin University, Changchun

Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou

Jinhua Municipal Centeral Hospital Medical Group, Jinhua